These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 21810031)

  • 1. Cytochrome P450-mediated cardiovascular drug interactions.
    Scheen AJ
    Expert Opin Drug Metab Toxicol; 2011 Sep; 7(9):1065-82. PubMed ID: 21810031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The role of genetic polymorphisms of cytochrome P450 in drug metabolism used in the treatment of cardiovascular diseases].
    Wojtczak A; Skretkowicz J
    Kardiol Pol; 2009 Sep; 67(9):1011-4. PubMed ID: 19838960
    [No Abstract]   [Full Text] [Related]  

  • 3. Cardiovascular drug therapy in the elderly.
    Aronow WS; Frishman WH; Cheng-Lai A
    Cardiol Rev; 2007; 15(4):195-215. PubMed ID: 17575484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytochrome p450-mediated cardiovascular drug interactions.
    Cheng JW
    Heart Dis; 2000; 2(3):254-8. PubMed ID: 11728266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Updates on cytochrome P450-mediated cardiovascular drug interactions.
    Cheng JW; Frishman WH; Aronow WS
    Am J Ther; 2009; 16(2):155-63. PubMed ID: 19114873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical application of cardiovascular pharmacogenetics.
    Voora D; Ginsburg GS
    J Am Coll Cardiol; 2012 Jul; 60(1):9-20. PubMed ID: 22742397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Issues in drug metabolism of major antihypertensive drugs: beta-blockers, calcium channel antagonists and angiotensin receptor blockers.
    Höcht C; Bertera FM; Mayer MA; Taira CA
    Expert Opin Drug Metab Toxicol; 2010 Feb; 6(2):199-211. PubMed ID: 20095790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuropsychiatric manifestations of cardiovascular drug therapy.
    Keller S; Frishman WH; Epstein J
    Heart Dis; 1999; 1(4):241-54. PubMed ID: 11720631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and risk of potential cytochrome P450-mediated drug-drug interactions in older hospitalized patients with polypharmacy.
    Doan J; Zakrzewski-Jakubiak H; Roy J; Turgeon J; Tannenbaum C
    Ann Pharmacother; 2013 Mar; 47(3):324-32. PubMed ID: 23482734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Grapefruit-drug interactions.
    Straughan JL
    Cardiovasc J S Afr; 2007; 18(1):39-40. PubMed ID: 17392996
    [No Abstract]   [Full Text] [Related]  

  • 11. [Interactions between anti-hypertensive and non-antihypertensive drugs].
    Sugimoto T; Matsuoka H
    Nihon Rinsho; 1992 May; 50 Suppl():28-33. PubMed ID: 1355128
    [No Abstract]   [Full Text] [Related]  

  • 12. Cardiovascular medications.
    Williams S; Wynn G; Cozza K; Sandson NB
    Psychosomatics; 2007; 48(6):537-47. PubMed ID: 18071104
    [No Abstract]   [Full Text] [Related]  

  • 13. Does differing metabolism by cytochrome p450 have clinical importance?
    Davidson MH
    Curr Atheroscler Rep; 2000 Jan; 2(1):14-9. PubMed ID: 11122720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The utility of cardiovascular drugs in the treatment of cerebrovascular disease.
    Bösel J; Amiri H
    Curr Opin Investig Drugs; 2010 Sep; 11(9):1015-24. PubMed ID: 20730696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular therapeutics.
    Shakur R; Cockrum E; Scott D
    Br J Hosp Med (Lond); 2008 Sep; 69(9):M136-40. PubMed ID: 18819300
    [No Abstract]   [Full Text] [Related]  

  • 16. Cardiovascular drug therapy in the elderly: theoretical and practical considerations.
    Williams BR; Kim J
    Drugs Aging; 2003; 20(6):445-63. PubMed ID: 12710864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drugs used in heart disease. 2. Pharmacology.
    Shulman R; Davies R; Landowski R
    Nurs Times; 2002 May 7-13; 98(19):41-4. PubMed ID: 12035397
    [No Abstract]   [Full Text] [Related]  

  • 18. Description of time- and frequency- domain-based measures of heart rate variability in individuals taking antiarrhythmics, beta blockers, calcium channel blockers, and/or antihypertensive drugs after sudden cardiac arrest.
    Cowan MJ; Pike K; Burr RL; Cain KC; Narayanan SB
    J Electrocardiol; 1993; 26 Suppl():1-13. PubMed ID: 7910623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic relevance of pharmacogenetic factors in cardiovascular medicine.
    Nakagawa K; Ishizaki T
    Pharmacol Ther; 2000 Apr; 86(1):1-28. PubMed ID: 10760544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapeutic measures following acute myocardial infarct: differential use of PTCA, surgery and drugs].
    Noll G; Kaufmann U; Wenzel RR; Lüscher TF
    Schweiz Med Wochenschr; 1996 Feb; 126(5):164-76. PubMed ID: 8685687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.